Complement C9 (C9) Mouse Monoclonal Antibody [Clone ID: aE11]

CAT#: AM26225FC-N

Complement C9 (C9) mouse monoclonal antibody, clone aE11, FITC


USD 515.00

2 Weeks*

Size
    • 100 ug

Product Images

Specifications

Product Data
Clone Name aE11
Applications ELISA, FN, IF, IHC
Recommended Dilution Immunohistochemistry on frozen sections (6): The typical starting working dilution is 1:50.
Immunohistochemistry on  paraffin sections (4): The typical starting working dilution is 1:50.
Flow cytometry (5): The typical starting working dilution is 1:50.
Functional assays (3,5).
Immunoassays (1,2).
Immunoflourescence (2,4).
Positive control: Mucosa from patients with H. Pylori.
Does not work in Western blot (2).
Reactivities Equine, Human, Porcine
Host Mouse
Isotype IgG2a
Clonality Monoclonal
Specificity
Monoclonal antibody aE11 reacts with a C9 neoantigen of the terminal complement complex (TCC).
Formulation PBS
Label: FITC
State: Liquid 0.2 µm filtered Ig fraction
Stabilizer: 0.1% bovine serum albumin
Preservative: 0.02% sodium azide
Concentration lot specific
Purification Protein G
Conjugation FITC
Storage

Store at 2 - 8 °C.

Stability Shelf life: one year from despatch.

Gene Name complement component 9
Background The three distinct activation pathways of complement converge with the formation of a C5 convertase. The cleavage of C5 by this convertase initiates the lytic or terminal pathway. In contrast to the activation pathways, which require enzymatic cleavage for activation, the terminal pathway relies on conformational changes induced by binding. Binding of C6 facilitates binding of C7 which alters the conformation of the complex. After binding of C8, a variable number of C9 molecules associate with the C5b678 complex, which is also termed  the terminal complement complex (TCC). The formation of TCC causes lysis of cells or can trigger a variety of cellular metabolic pathways resulting in the synthesis and release of inflammatory mediators. The TCC contains neoantigens that are absent from the individual native components.  C9 neoantigens are present both in the membrane-bound (MAC) and the fluid-phase (SC5b-9) complex. TCC is present in normal human plasma and increased in patients with complement activation.
Synonyms Complement component C9, Complement 9
Reference Data

{0} Product Review(s)

0 Product Review(s) Submit review

Be the first one to submit a review

Product Citations

*Delivery time may vary from web posted schedule. Occasional delays may occur due to unforeseen complexities in the preparation of your product. International customers may expect an additional 1-2 weeks in shipping.